Inicio>>EPI-X4 (trifluoroacetate salt)

EPI-X4 (trifluoroacetate salt) (Synonyms: Endogenous Peptide Inhibitor of CXCR4)

Catalog No.GC91465

EPI-X4 es un fragmento de péptido endógeno que corresponde a los aminoácidos 408-423 de la albúmina sérica humana y es un antagonista del receptor 4 de quimiocina (motivo C-X-C) (CXCR4).

Products are for research use only. Not for human use. We do not sell to patients.

EPI-X4 (trifluoroacetate salt) Chemical Structure

Tamaño Precio Disponibilidad Cantidad
1mg
41,00 $
Disponible
5mg
153,00 $
Disponible
10mg
224,00 $
Disponible
25mg
456,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
EPI-X4 is an endogenous peptide fragment corresponding to amino acids 408-423 of human serum albumin and an antagonist of chemokine (C-X-C motif) receptor 4 (CXCR4).1 It inhibits calcium mobilization and receptor internalization induced by chemokine (C-X-C motif) ligand 12 (CXCL12) in HEK293 cells expressing CXCR4 when used at concentrations ranging from 0.8 to 1,000 µM. EPI-X4 inhibits CXCL12-induced migration of Jurkat T cells and human CD34+ hematopoietic stem cells. In vivo, EPI-X4 (16 µmol/kg) reduces Cxcr4-dependent inflammatory cell airway infiltration in a mouse model of acute allergic airway hypereosinophilia. Urinary levels of EPI-X4 are increased and inversely correlated with glomerular filtration rate (GFR) in patients with chronic kidney disease.

Reseñas

Review for EPI-X4 (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for EPI-X4 (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.